Abstract:Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this platform necessitates innovative molecular designs to tackle several clinical challenges such as drug resistance, tumour heterogeneity and treatment-related adverse effects. Several emerging ADC formats exist, including bispecific ADCs, conditionally active ADCs (also known as probody–drug conjugates), immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs, and each offers unique capabilities for tackling these various challenges. For example, probody–drug conjugates can enhance tumour specificity, whereas bispecific ADCs and dual-drug ADCs can address resistance and heterogeneity with enhanced activity. The incorporation of immune-stimulating and protein-degrader ADCs, which have distinct mechanisms of action, into existing treatment strategies could enable multimodal cancer treatment. Despite the promising outlook, the importance of patient stratification and biomarker identification cannot be overstated for these emerging ADCs, as these factors are crucial to identify patients who are most likely to derive benefit. As we continue to deepen our understanding of tumour biology and refine ADC design, we will edge closer to developing truly effective and safe ADCs for patients with treatment-refractory cancers. In this Review, we highlight advances in each ADC component (the monoclonal antibody, payload, linker and conjugation chemistry) and provide more-detailed discussions on selected examples of emerging novel ADCs of each format, enabled by engineering of one or more of these components.

Antibody-drug Conjugates: Design and Clinical Progress

Development of antibody-drug conjugates in cancer: Overview and prospects

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Antibody-drug Conjugates and Their Application in the Treatment of Hematological Malignancies

Antibody-drug conjugates: Principles and opportunities

Bibliometric analysis of antibody-drug conjugates

Marine Antibody–Drug Conjugates: Design Strategies and Research Progress

Drug conjugate-based anticancer therapy - Current status and perspectives

Research progress on novel antibody drug conjugates in cancer therapy

Antibody drug conjugates in the clinic

Advances and Limitations of Antibody Drug Conjugates for Cancer

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Development of antibody used by antibody-drug conjugates

Antibody-Drug Conjugates: A promising breakthrough in cancer therapy

Antibody-Drug Conjugates: The New Frontier of Chemotherapy

Antibody-drug conjugates—an emerging class of cancer treatment

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Exploring the next generation of antibody–drug conjugates

A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy

Targeting cancer with antibody-drug conjugates: Promises and challenges